Christopher Morgan & Leigh Anne Ihnken, Research Scientists, GlaxoSmithKline, 29Of course, they're pharma process chemists, not synthetic biologists (or are they???) And of course, modification of enzymes to drive better enantioselectivity has been around for quite some time. (I clearly remember being blown away by a Manfred Reetz talk at the Bozeman, MT National Organic Symposium in 2001.)
Using synthetic biology to make pharmaceutical chemistry less expensive and less harmful to the environment.
But that's too complex for Forbes, apparently. So it's "biology/science to the rescue of dirty chemistry" as opposed to "chemists improving chemistry." Disappointing.
[Sorry, a more substantive PW next week, I promise.]